Vanda Pharmaceuticals
Vanda Pharmaceuticals' revenue rose 8.7% to $216 million in fiscal 2025. Its operating margin was −70.0%, down from −20.5% a year earlier. Free cash flow was −$110 million. The diluted share count rose 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2018 to 2023, earnings per share fell 39.2% a year and net income 37.0% a year, as new shares raised the share count by 9% and diluted each share's earnings. Vanda Pharmaceuticals then lost money in fiscal 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 433 | 467 | 388 | 375 | 264 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 6.4x | 5.7x | 4.9x | 4.4x | 2.4x |
| Quick ratio | 6.4x | 5.7x | 4.9x | 4.4x | 2.4x |
Cash flow
Projections
Project Vanda Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Vanda Pharmaceuticals shares on the open market, and 6 insiders sold $2.8 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Mihael Hristos PolymeropoulosPresident and CEO, Director | Sold | 156,235 | $8.17 | $1.3 million | Form 4 |
| Mar 2, 2026 | Kevin Patrick MoranSVP, CFO & Treasurer | Sold | 42,442 | $8.27 | $350,995 | Form 4 |
| Mar 2, 2026 | Timothy WilliamsSVP & General Counsel | Sold | 42,434 | $8.27 | $350,929 | Form 4 |
| Mar 2, 2026 | Gunther BirznieksSVP, Business Development | Sold | 42,431 | $8.27 | $350,904 | Form 4 |
| Mar 2, 2026 | Joakim WijkstromSVP, Chief Marketing Officer | Sold | 30,800 | $8.27 | $254,716 | Form 4 |
| Feb 23, 2026 | Tage HonoreDirector | Sold | 30,000 | $8.03 | $240,900 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −17.8% | −5.0% | −42.4% |
| Altman Z'' | 8.09 | 6.91 | 0.13 |
| Accruals ratio | −1.6% | −0.5% | −19.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Fail |
| Cash from operations is positive | Pass | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Vanda Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals | FY25 | 8.7% | −70.0% | −51.1% | — | — | — | |
| Amarin | FY25 | −6.5% | −23.5% | — | — | — | — | Compare |
| IDEAYA Biosciences | FY25 | 3,024.4% | −72.8% | −33.6% | — | — | — | Compare |
| Puma Biotechnology | FY25 | −0.9% | 16.3% | 18.3% | 48.2% | −1.4x | 8 | Compare |
| Akebia Therapeutics | FY25 | 47.5% | 9.9% | 28.7% | — | −5.5x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 146 | 165 | 193 | 227 | 248 | 269 | 254 | 193 | 199 | 216 |
| Revenue growth | 32.8% | 13.1% | 17.0% | 17.6% | 9.2% | 8.3% | −5.3% | −24.3% | 3.2% | 8.7% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 29 | 38 | 44 | 49 | 56 | 75 | 86 | 77 | 74 | 109 |
| Operating income | −19 | −17 | 22 | 23 | 27 | 42 | 6 | −14 | −41 | −151 |
| Net income | −18 | −16 | 25 | 116 | 23 | 33 | 6 | 2 | −19 | −220 |
| Diluted EPS (US$) | −0.41 | −0.35 | 0.48 | 2.11 | 0.42 | 0.58 | 0.11 | 0.04 | −0.33 | −3.74 |
| Diluted shares (millions) | 43 | 45 | 53 | 55 | 55 | 57 | 57 | 58 | 58 | 59 |
| Cash flow | ||||||||||
| Cash from operations | −8 | −2 | 30 | 46 | 52 | 64 | 32 | 13 | −16 | −109 |
| Capital expenditure | 1 | 2 | 0 | 1 | 2 | 1 | 1 | 0 | 0 | 1 |
| Free cash flow | −10 | −4 | 30 | 45 | 50 | 64 | 31 | 12 | −16 | −110 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 10 | 12 | 14 | 13 | 15 | 16 | 14 | 12 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 141 | 143 | 257 | 312 | 368 | 433 | 467 | 388 | 375 | 264 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 210 | 205 | 332 | 484 | 534 | 594 | 634 | 648 | 656 | 489 |
| Total liabilities | 79 | 74 | 57 | 73 | 80 | 89 | 107 | 104 | 118 | 162 |
| Shareholders' equity | 131 | 131 | 275 | 411 | 453 | 505 | 527 | 545 | 538 | 327 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −12.7% | −10.2% | 11.3% | 10.0% | 11.0% | 15.7% | 2.5% | −7.2% | −20.5% | −70.0% |
| Net margin | −12.3% | −9.4% | 13.1% | 50.9% | 9.4% | 12.3% | 2.5% | 1.3% | −9.5% | −102.0% |
| Free cash flow margin | −6.5% | −2.2% | 15.3% | 19.8% | 20.1% | 23.7% | 12.3% | 6.5% | −8.2% | −51.1% |
| Rule of 40 (growth + FCF margin) | 26.3% | 10.8% | 32.3% | 37.4% | 29.4% | 32.0% | 7.0% | −17.8% | −5.0% | −42.4% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −13.6% | −11.8% | 12.4% | 33.7% | 5.4% | 6.9% | 1.2% | 0.5% | −3.5% | −50.9% |
| Return on assets | −8.5% | −7.5% | 9.4% | 28.3% | 4.6% | 5.9% | 1.0% | 0.4% | −2.9% | −38.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |